Capital Group Private Client Services Inc. Boosts Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

Capital Group Private Client Services Inc. grew its holdings in Moderna, Inc. (NASDAQ:MRNA) by 24.8% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 37,883 shares of the company’s stock after purchasing an additional 7,524 shares during the period. Capital Group Private Client Services Inc.’s holdings in Moderna were worth $4,037,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of MRNA. Ogorek Anthony Joseph NY ADV purchased a new position in Moderna during the 4th quarter valued at about $27,000. Cedar Wealth Management LLC grew its stake in Moderna by 45.0% during the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock valued at $31,000 after acquiring an additional 90 shares in the last quarter. Arlington Trust Co LLC increased its holdings in Moderna by 4,833.3% during the 4th quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock worth $29,000 after acquiring an additional 290 shares during the period. Westside Investment Management Inc. purchased a new stake in Moderna in the 1st quarter worth approximately $32,000. Finally, Rise Advisors LLC boosted its holdings in Moderna by 953.3% in the 1st quarter. Rise Advisors LLC now owns 316 shares of the company’s stock valued at $34,000 after purchasing an additional 286 shares during the period. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Moderna news, CFO James M. Mock sold 648 shares of the firm’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $162.47, for a total value of $105,280.56. Following the completion of the sale, the chief financial officer now directly owns 5,726 shares in the company, valued at $930,303.22. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $110.92, for a total value of $1,663,800.00. Following the sale, the director now directly owns 2,026,931 shares of the company’s stock, valued at approximately $224,827,186.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO James M. Mock sold 648 shares of Moderna stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $162.47, for a total transaction of $105,280.56. Following the transaction, the chief financial officer now directly owns 5,726 shares of the company’s stock, valued at $930,303.22. The disclosure for this sale can be found here. In the last ninety days, insiders sold 381,239 shares of company stock worth $53,661,337. 15.70% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

MRNA has been the topic of a number of recent analyst reports. Piper Sandler reiterated an “overweight” rating and issued a $214.00 price objective on shares of Moderna in a research report on Thursday, June 27th. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research report on Friday, June 28th. Oppenheimer boosted their price objective on Moderna from $163.00 to $179.00 and gave the stock an “outperform” rating in a report on Wednesday, June 12th. Royal Bank of Canada lifted their target price on shares of Moderna from $135.00 to $160.00 and gave the company an “outperform” rating in a research report on Monday, June 3rd. Finally, UBS Group increased their price target on shares of Moderna from $143.00 to $151.00 and gave the stock a “buy” rating in a report on Tuesday, May 7th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $133.88.

Moderna Trading Up 1.4 %

NASDAQ:MRNA traded up $1.71 during midday trading on Friday, reaching $122.11. 1,884,844 shares of the stock traded hands, compared to its average volume of 4,016,060. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.91 and a current ratio of 4.03. The company has a fifty day moving average of $134.78 and a 200 day moving average of $114.96. The stock has a market capitalization of $46.80 billion, a P/E ratio of -7.75 and a beta of 1.66. Moderna, Inc. has a 12 month low of $62.55 and a 12 month high of $170.47.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, May 2nd. The company reported ($3.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.59) by $0.52. The firm had revenue of $167.00 million for the quarter, compared to analyst estimates of $93.26 million. Moderna had a negative return on equity of 20.10% and a negative net margin of 115.82%. The business’s quarterly revenue was down 91.0% compared to the same quarter last year. During the same period last year, the company earned $0.19 EPS. On average, research analysts predict that Moderna, Inc. will post -7.46 EPS for the current year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.